The role of chemotherapy toxicity scales in decision-making for acute leukemia and lymphoma: a scoping review

Acute leukemias and non-Hodgkin lymphomas together rank 4th among the most common neoplasms. With curative treatment options, even in adverse situations, however, the decision-making process is delicate and statistical models can help. To identify the chemotherapy toxicity scales and their role in decision-making for the treatment of patients with acute lymphomas and leukemias, we conducted a scoping review on the PUBMED, BIREME, COCHRANE, and CAPES journal data platforms. Thirty articles were selected using the PRISMA protocol approach. There is no ideal scale for assessing chemotherapy toxicity, but there are common variables, such as comorbidities, functionality, age, LDH, renal function, and disease staging. Predictive models of treatment toxicity in patients with acute leukemia and lymphoma require more robust and prospective studies that include the validation of these models for better applicability.